| budesonide ER / Generic mfg. |
NCT00679380 / 2006-004776-12: (CB-01-02/02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis |
|
|
| Completed | 3 | 514 | Europe, RoW | Blood sampling, endoscopy, Budesonide MMX® 6 mg, Budesonide MMX® 9 mg, Entocort EC® 3 mg, Placebo | Bausch Health Americas, Inc., Cosmo Technologies Ltd | Ulcerative Colitis | 02/10 | 04/10 | | |
NCT00679432: (CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis |
|
|
| Completed | 3 | 510 | Canada, US, RoW | Blood sampling, endoscopy, budesonide-MMX® 6 mg, budesonide-MMX® 9 mg, Placebo, Asacol® 400 mg | Bausch Health Americas, Inc. | Ulcerative Colitis | 05/10 | 06/10 | | |
NCT01100112: (CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets |
|
|
| Completed | 3 | 61 | RoW | Budesonide | Bausch Health Americas, Inc., Cosmo Technologies Ltd | Colitis, Ulcerative | 07/10 | 08/10 | | |
NCT00801723 / 2008-003913-28: (CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis. |
|
|
| Completed | 3 | 123 | Canada, US | Budesonide MMX 6 mg Tablet, Placebo Tablet | Bausch Health Americas, Inc. | Ulcerative Colitis | 05/11 | 06/11 | | |
NCT01532648 / 2011-005115-82: Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA) |
|
|
| Completed | 3 | 510 | Europe, Canada, US, RoW | Budesonide MMX®, Budesonide Multi-Matrix System, Placebo, 5-ASA | Bausch Health Americas, Inc. | Ulcerative Colitis | 10/13 | 10/13 | | |
2017-004576-57: Novel budesonide capsules vs. budesonide tablets in patients with ulcerative colitis refractory to standard treatment with mesalazine Neue Budesonid Kapseln vs. Budesonid Tabletten bei Colitis-ulcerosa-Patienten, die gegen die Standardbehandlung mit Mesalazin refraktär sind |
|
|
| Ongoing | 3 | 777 | Europe | Budesonide 9 mg capsules, hard (BUX-PVII prototype), Budesonide 6 mg capsules, hard (BUX-PVII prototype), Prolonged-release capsule, hard, Prolonged-release tablet, CortimentMMX 9 mg | Dr. Falk Pharma GmbH, Dr. Falk Pharma GmbH | Patients with active ulcerative colitis refractory to standard treatment with mesalazine, Patients with ulcerative colitis refractory to standard treatment with mesalazine, Diseases [C] - Digestive System Diseases [C06] | | | | |
NCT05341401: Budesonide Multimatrix(MMX) Versus Prednisolone in Management of Mild to Moderate Ulcerative Colitis |
|
|
| Not yet recruiting | 2/3 | 100 | NA | Budesonide MMX, Prednisolone | Assiut University | Ulcerative Colitis Chronic | 06/23 | 06/24 | | |
